# Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

> **NCT06554509** · PHASE2,PHASE3 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 423 (estimated)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** SHR-1819 Injection
- **DRUG:** SHR-1819 Injection Placebo

## Key facts

- **NCT ID:** NCT06554509
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 423 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06554509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06554509, "Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06554509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*